| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4933150 | Psychiatry Research | 2017 | 5 Pages |
Abstract
VCD's ability like VPA to reduce rat brain AA turnover and inhibit recombinant Acsl-4, and its efficacy in BD, suggest that VCD be further considered as a non-teratogenic VPA substitute for treating BD.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Hiren R. Modi, Kaizong Ma, Lisa Chang, Mei Chen, Stanley I. Rapoport,